Disease burden, monitoring strategy, and timing of therapy drive CRS risk and management.
Allison Yang, PharmD
Advertisement
Articles by Allison Yang, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Early Recognition and Routine Discussion: Improving Outcomes in Tardive Dyskinesia
2
Do GLP-1 Receptor Agonists Increase the Risk of Smell and Taste Disturbances?
3
Melatonin May Reduce Musculoskeletal Pain and Improve Sleep
4
Meet the FDA’s Newly Approved OTC Sunscreen Ingredient: Bemotrizinol
5